Loading...
XHKG
6118
Market cap64mUSD
Dec 05, Last price  
0.98HKD
1D
1.03%
1Q
-19.01%
Jan 2017
-15.52%
IPO
-70.39%
Name

Austar Lifesciences Ltd

Chart & Performance

D1W1MN
XHKG:6118 chart
P/E
28.37
P/S
0.30
EPS
0.03
Div Yield, %
Shrs. gr., 5y
Rev. gr., 5y
7.42%
Revenues
1.50b
-14.93%
705,153,000679,750,000627,544,000672,545,000546,933,000816,585,0001,049,021,0001,295,980,0002,015,028,0002,228,644,0001,763,734,0001,500,402,000
Net income
16m
P
53,571,00065,193,0006,384,000-18,670,000-54,085,000107,0008,091,00033,100,000277,300,00087,461,000-113,473,00016,079,000
CFO
99m
P
71,407,000-64,400,99961,526,000-30,462,000-6,171,000-77,598,00037,793,00052,224,000-103,451,000-37,926,000-62,649,00098,805,000
Dividend
May 19, 20150.05 HKD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Austar Lifesciences Limited, an investment holding company, provides integrated engineering solutions to pharmaceutical manufacturers and research institutes in Mainland China and internationally. It operates through six segments: Liquid and Bioprocess System; Clean Room and Automation Control and Monitoring System; Powder and Solid System; GMP Compliance Service; Life Science Consumables; and Distribution and Agency of Pharmaceutical Equipment. The company offers liquid and bioprocess systems, including pharmaceutical water, and liquid preparation and bioprocess systems; powder and solid systems; clean utility equipment and systems; clean room, automation control, and monitor systems; and freeze-dryer, sterile filling, and visual inspection equipment. It also provides pharmaceutical process contamination control products; packaging and aseptic containment products; biosafety and lab animal equipment and consumables; laboratory one-stop solutions; and single-use bioprocess equipment and consumables. In addition, the company offers design, quality risk control, consulting, research and development support, process engineering, digitalization construction, after-sale, on-site, upgrading, relocation, and asset management services. Further, it is involved in the agency and distribution of pharmaceutical equipment, as well as provides assembly and pre-assembly services. The company was founded in 1991 and is headquartered in Shanghai, China.
IPO date
Nov 07, 2014
Employees
1,838
Domiciled in
CN
Incorporated in
KY

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT